Inside information filing with the CSRC in relation to the proposed implementation of h share full circulation
Filed with HKEX · Stock code 6887 · · 2 pages · English
SUNSHINE LAKE PHARMA CO.,LTD. 廣東東陽光藥業股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 6887) INSIDE INFORMATION FILING WITH THE CSRC IN RELATION TO THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION This announcement is made by Sunshine Lake Pharma Co., Ltd. (the ‘‘Company’’) in accordance with Rule 13.09(2) of the Rules Governin
Sunshine Lake Pharma Co., Ltd. on 6ix
Earlier from Sunshine Lake Pharma
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
- Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
Later from Sunshine Lake Pharma
- Next Day Disclosure Return
- Interim Report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement Insulin Degludec and Insulin Aspart Injection obtained marketing approval from the china national medical products administration
Follow Sunshine Lake Pharma into a list and get an email when it puts out news.
Follow Sunshine Lake Pharma